ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Meidhof, Simone, Brabletz, Simone, Lehmann, Waltraut, Preca, Bogdan-Tiberius, Mock, Kerstin, Ruh, Manuel, Schüler, Julia, Berthold, Maria, Weber, Anika, Burk, Ulrike, Lübbert, Michael, Puhr, Martin, Culig, Zoran, Wellner, Ulrich, Keck, Tobias, Bronsert, Peter, Küsters, Simon, Hopt, Ulrich T, Stemmler, Marc P, Brabletz, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2015
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://ncbi.nlm.nih.gov/pubmed/25872941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201404396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados